GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (NAS:VIRX) » Definitions » Asset Turnover

Viracta Therapeutics (Viracta Therapeutics) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Viracta Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Viracta Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $49.01 Mil. Therefore, Viracta Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Viracta Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was -248.74%. It is also linked to ROA % through Du Pont Formula. Viracta Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -74.60%.


Viracta Therapeutics Asset Turnover Historical Data

The historical data trend for Viracta Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Asset Turnover Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - - -

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Viracta Therapeutics's Asset Turnover

For the Biotechnology subindustry, Viracta Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viracta Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's Asset Turnover falls into.



Viracta Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Viracta Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (95.991+56.692)/ 2 )
=0/76.3415
=0.00

Viracta Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (56.692+41.334)/ 2 )
=0/49.013
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Viracta Therapeutics  (NAS:VIRX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Viracta Therapeutics's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-36.564/14.6995
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-36.564 / 0)*(0 / 49.013)*(49.013/ 14.6995)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*3.3343
=ROA %*Equity Multiplier
=-74.60 %*3.3343
=-248.74 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Viracta Therapeutics's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-36.564/49.013
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-36.564 / 0)*(0 / 49.013)
=Net Margin %*Asset Turnover
= %*0
=-74.60 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Viracta Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Viracta Therapeutics (Viracta Therapeutics) Business Description

Traded in Other Exchanges
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.
Executives
Mark Rothera director, officer: President and CEO C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Daniel R. Chevallard officer: Chief Executive Officer C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Darrel P. Cohen officer: Chief Medical Officer C/O VIRACTA THERAPEUTICS, INC., 2533 S. COAST HWY 101, SUITE 210, CARDIFF CA 92007
Lisa Rojkjaer officer: Chief Medical Officer C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Ivor Royston director, officer: CEO & President 4401 WILSHIRE BLVD., SUITE 200, LOS ANGELES CA 90010
Jane Chung director C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Flavia Borellini director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barry J. Simon director 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Stephen Rubino director C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Gur Roshwalb director, 10 percent owner C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael Huang director C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Thomas E Darcy director C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121

Viracta Therapeutics (Viracta Therapeutics) Headlines